Suomi - suomi - Fimea (Suomen lääkevirasto)

novartis finland oy - carbamazepine - tabletti - 100 mg - karbamatsepiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

orifarm oy - diclofenac diethylamine - geeli - 11.6 mg/g - diklofenaakki

Suomi - suomi - Fimea (Suomen lääkevirasto)

suomen punainen risti veripalvelu - plasmaproteinum ihmisen - injektiokuiva-aine ja liuotin, liuosta varten - 500 iu - hyytymistekijä ix

Suomi - suomi - Fimea (Suomen lääkevirasto)

suomen punainen risti veripalvelu - plasmaproteinum ihmisen - injektiokuiva-aine ja liuotin, liuosta varten - 1000 iu - hyytymistekijä ix

Suomi - suomi - Fimea (Suomen lääkevirasto)

roche oy - ganciclovirum - kapseli, kova - 250 mg - gansikloviiri

Suomi - suomi - Fimea (Suomen lääkevirasto)

schering oy - isosorbidi dinitras - infuusioneste - 0.4 mg/ml - isosorbididinitraatti

Suomi - suomi - Fimea (Suomen lääkevirasto)

ucb s.a. - pseudoephedrini hydrochloridum,cetirizini dihydrochloridum - depotkapseli, kova - pseudoefedriini, yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - sumatriptani succinas - tabletti - 100 mg - sumatriptaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - sumatriptani succinas - injektioneste - 12 mg/ml - sumatriptaani

Euroopan unioni - suomi - EMA (European Medicines Agency)

stada arzneimittel ag - adalimumabi - arthritis, psoriatic; arthritis, juvenile rheumatoid; arthritis, rheumatoid; colitis, ulcerative; crohn disease; hidradenitis suppurativa; psoriasis; spondylitis, ankylosing; uveitis - immunosuppressantit - rheumatoid arthritishukyndra in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs (dmards) including methotrexate has been inadequate. - the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. adalimumabi on osoitettu hidastavan etenemistä nivelvaurioita mitattuna x-ray ja parantaa fyysistä toimintakykyä, kun sitä annetaan yhdessä metotreksaatin kanssa. juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritishukyndra in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more dmard. hukyndra can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5. humiraa ei ole tutkittu potilailla, joiden ikä on alle 2 vuotta. enthesitis-related arthritishukyndra is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritisankylosing spondylitis (as)hukyndra is indicated for the treatment of adults with severe active as who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of ashukyndra is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (nsaids). psoriatic arthritishukyndra is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous dmard therapy has been inadequate. adalimumabi on osoitettu hidastavan taudin perifeeristen nivelvaurioiden mitattuna x-ray potilailla, joilla idiopaattisen symmetrinen alatyypit sairauden (ks. kohta 5. 1) ja parantavan fyysistä toimintakykyä. psoriasishukyndra is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasishukyndra is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs)hukyndra is indicated for the treatment of active moderate to severe hs (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 ja 5. crohn’s diseasehukyndra is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's diseasehukyndra is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitishukyndra is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. paediatric ulcerative colitishukyndra is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitishukyndra is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitishukyndra is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.